Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dutt, M.
Right arrow Articles by Khuller, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutt, M.
Right arrow Articles by Khuller, G. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 829-835
© 2001 The British Society for Antimicrobial Chemotherapy

Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles

Manisha Dutt and G. K. Khuller,*

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India

Strategies to improve patient compliance in tuberculosis chemotherapy include the use of sustained release drug delivery systems. In this study, Poly (DL-lactide-co-glycolide) (PLG) microparticles containing a combination of isoniazid and rifampicin were developed as sustained release carrier systems. A single dose of PLG microparticles exhibited a sustained release of isoniazid and rifampicin in vivo up to 7 and 6 weeks, respectively. Free drugs (in combination) injected in the same doses were detectable in vivo up to 24 h only. One dose of PLG microparticles cleared bacteria more effectively from lungs and liver in an experimental murine model of tuberculosis after low-dose PLG combination drug therapy and in liver after high-dose PLG combination drug therapy as compared with a daily administration of the free drugs. These results suggest that PLG microparticles offer an improvement for tuberculosis chemotherapy over the conventional treatment.

* *Corresponding author. Tel: +91-172-747585, ext. 282, 274; Fax: +91-172-744401/745078; E-mail: medinst{at}pgi.chd.nic.in


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Gelperina, K. Kisich, M. D. Iseman, and L. Heifets
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1487 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Pandey and G. K. Khuller
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model
J. Antimicrob. Chemother., July 1, 2004; 54(1): 266 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Q. ul-Ain, S. Sharma, and G. K. Khuller
Chemotherapeutic Potential of Orally Administered Poly(Lactide-Co-Glycolide) Microparticles Containing Isoniazid, Rifampin, and Pyrazinamide against Experimental Tuberculosis
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 3005 - 3007.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
Qurrat-ul-Ain, S. Sharma, G. K. Khuller, and S. K. Garg
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects
J. Antimicrob. Chemother., April 1, 2003; 51(4): 931 - 938.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.